文献速递鼻科

阿司匹林加重性呼吸系统疾病不脱敏的术后结局

Surgical outcomes in aspirin-exacerbated respiratory disease without aspirin desensitization.
PubMed 文献 · Int Forum Allergy Rhinol · 2020-06-18

回顾性分析141例未行阿司匹林脱敏的AERD患者接受内镜鼻窦手术后的结局,26.2%需再次手术,中位再手术时间3.3年;术后SNOT-22评分显著改善,但再手术组1年时改善未维持。

要点

  • AERD患者不脱敏仅ESS+药物,5年无再手术概率44.8%。
  • 术后6个月SNOT-22降34分,1年降27分。
  • 单克隆抗体治疗与再手术时间无差异(p=0.23)。

核心结论

  • 相当比例AERD患者仅ESS和药物治疗不脱敏即可获益。

研究设计与样本

  • 回顾性综述2010-2019年未行AD的AERD患者接受ESS的病例,共141例。

主要发现

  • 37例(26.2%)行再次ESS,中位再手术时间3.3年(IQR 2.2-4.9)。
  • 1年、3年、5年无再手术概率分别为98.2%(95%CI 95.7-100.0%)、78.8%(95%CI 70.2-88.4%)、44.8%(95%CI 32.4-62.1%)。
  • SNOT-22评分术后6个月降34分(IQR 18-52),1年降27分(IQR 20-46)。
  • 再手术组SNOT-22评分改善在术后1年未维持。
  • 与未使用MAT者相比,再手术时间无差异(p=0.23)。

临床怎么用

  • AERD患者可考虑ESS联合药物治疗而不必常规行AD,但需告知再手术风险。
  • 单克隆抗体治疗对手术结局的影响需进一步研究,目前证据有限。

局限性

  • 样本量小,MAT亚组分析受限。
  • 回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) represents a severe endotype of chronic rhinosinusitis with nasal polyposis. Although aspirin desensitization (AD) has emerged as an effective therapeutic option, the natural history of AERD without AD remains unclear. METHODS: A retrospective review was conducted of AERD patients who underwent endoscopic sinus surgery (ESS) without AD between 2010 and 2019. The primary outcomes were revision surgery rate and time to revision surgery. Secondary outcomes included changes in 22-item Sino-Nasal Outcome Test (SNOT-22) scores and Lund-Kennedy endoscopy scores (LKES). A subgroup analysis was performed for patients on monoclonal antibody therapy (MAT). RESULTS: Of 141 patients, 37 (26.2%) underwent revision ESS with a median time to revision of 3.3 (interquartile range [IQR], 2.2-4.9) years. The probability of remaining free of revision surgery at 1, 3, and 5 years was: 98.2% (95% confidence interval [CI], 95.7-100.0%), 78.8% (95% CI, 70.2-88.4%), and 44.8% (95% CI, 32.4-62.1%), respectively. SNOT-22 scores decreased by 34 (IQR, 18-52) points at 6 months and 27 (IQR, 20-46) points at 1 year postoperatively. In the revision cohort, the decrease in SNOT-22 score was not sustained at 1 year postoperatively. No difference was found in time to revision compared with those without MAT (p = 0.23). CONCLUSION: A significant proportion of AERD patients benefit from ESS and medical therapy alone without AD. This study presents preliminary results on the impact of MAT on surgical outcomes as it is limited by the small sample size. Further research on the use of MAT in AERD is needed.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Grose E, Lee DJ, Yip J, et al. Surgical outcomes in aspirin-exacerbated respiratory disease without aspirin desensitization. Int Forum Allergy Rhinol. 2020. PMID: 32558318. doi:10.1002/alr.22626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。